Showing 828 results
-
Media Release /- Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate…
-
Media Release /- FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible- Using patients' self-recorded measurements, FocalView aims to enable…
-
Media Release /-- EXPAND shows oral siponimod (BAF312) is the first investigational disease-modifying therapy in a large trial that meaningfully delayed disability progression in typical secondary progressive MS (…
-
Media Release /- Two thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows(1)- Study findings show absolute PASI ≤1/≤2/≤3…
-
Media Release /Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response1Kymriah is the only CAR-T…
-
Media Release /- Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48…
-
Media Release /- Results from the Kisqali® MONALEESA clinical trial program, the largest industry-sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be…
-
Media Release /The new product joins the #1 doctor recommended Systane family of dry eye drops as the brand's most advanced solution to dateAlcon launches multimedia campaign to reach the 30 million people living…
-
Media Release /- New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)(1)- In a landmark…
-
Media Release /- Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy…
